Rossari Biotech Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, during a board meeting held on April 27, 2026. The company’s consolidated revenue from operations for the quarter stood at ₹6,881.04 million, representing a 22.84% increase compared to ₹5,601.76 million in the corresponding quarter of the previous year (YoY) and a 16.71% rise from ₹5,895.84 million in the preceding quarter (QoQ). Consolidated net profit for the quarter reached ₹385.79 million, marking a substantial 53.27% YoY growth from ₹251.70 million and an 41.59% QoQ increase from ₹272.46 million. Alongside these results, the Board recommended a final dividend of 25% (₹0.50 per share) for the financial year 2025-26.

Rossari Biotech Limited is a leading Indian specialty chemicals manufacturer with a diversified portfolio spanning Home, Personal Care, and Performance Chemicals, Textile Specialty Chemicals, and Animal Health and Nutrition. The company recently announced the establishment of a new state-of-the-art Research and Development facility in Navi Mumbai and is relocating its existing R&D operations from IIT Bombay to this new center to enhance innovation and product development. Additionally, the company is rescheduling its proposed capacity expansion project to be undertaken in a phased manner over the next two years to better align with evolving market conditions. As part of its leadership strengthening, Mr. Udeypaul Singh Gill was appointed as an Independent Director effective April 28, 2026.